---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-086678"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2022-03-28T23:59:59+00:00"
generated_at: "2026-06-26T16:05:20.310428+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Acumen reports FY2021 net loss $100.6M; Phase 1 ACU193 topline results expected H1 2023

## Summary
- Cash, cash equivalents and marketable securities $225.9M at Dec 31, 2021; provides runway through 2025.
- Net loss $100.6M for FY2021 includes $81.2M non-cash fair value adjustment; operating loss $19.6M.
- R&D expenses $12.3M (up from $8.0M) driven by clinical trial initiation; G&A $7.3M (up from $1.4M).
- Topline results from INTERCEPT-AD Phase 1 trial of ACU193 now expected first half of 2023 due to slower enrollment from COVID-19.
- Kim Drapkin appointed to Board of Directors effective Apr 1, 2022; three new team members added in Q4 2021.

## SEC filing metadata
- accession: 0001193125-22-086678
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2022-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000119312522086678/0001193125-22-086678-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000119312522086678/d302531d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-086678
- JSON: https://secwatch.observer/filing/0001193125-22-086678.json
- Plain text: https://secwatch.observer/filing/0001193125-22-086678.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.